Description: Celcuity, Inc. is a United States-based early stage biotechnology company. The Company develops tests that functionally analyze diseased live cells. The Company has developed CELx Pathway Profile technology, which combines advancements in primary tissue research with a method of measuring a targeted therapy's functional pathway effect on live and diseased patient cells. The Company offers functional cellular analysis platform that assesses the functionality of the disease-related signaling pathways of patient's diseased cells ex vivo and determines whether a drug therapy has the effect on diseased cells. The Company's CELx test is designed to determine whether a pathway is functional to therapeutic intervention without regard to the exact mechanism a patient's tumor may have developed to resist the therapeutic effect. The Company’s diagnostic approach helps to identify cancer subtypes.
Home Page: www.celcuity.com
CELC Technical Analysis
16305–36th Avenue North
Minneapolis,
MN
55446
United States
Phone:
763 392 0767
Officers
| Name | Title |
|---|---|
| Mr. Brian F. Sullivan | Co-Founder, Chairman & CEO |
| Dr. Lance G. Laing Ph.D. | Co-Founder, Chief Science Officer, VP, Sec. & Director |
| Ms. Vicky Hahne | Chief Financial Officer |
| Dr. John R. MacDonald Dabt, Ph., Ph.D. | Sr. VP of R&D |
| Ms. Sheri Smith | Acting Head of Clinical Operations |
| Mr. Igor Gorbatchevsky M.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.3317 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2017-09-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 39 |